Description | Tissue
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Background | The development of biomarkers has enormous potential for revolutionizing the diagnosis and treatment of disease. Western blot analysis is an integral technique for biomarker profiling. While key for biomarker discovery, the existing body of western blot data has primarily been defined from studies of tumor, immortal, and primary cells growing in vitro. Collectively, results obtained over dec...ades have been integral to the dogma that up- and down-regulation of proteins can be leveraged as biomarkers of normal development, homeostasis, and disease. However, data from human tissue-derived products is key for generating biomarker validation data and progressing the most promising biomarker targets towards the clinic. The OncoPair INSTA-Blot&8286; product line addresses the increasing demand for the inclusion of human tissue-derived products in biomarker profiling.The OncoPair INSTA-Blot&8286; is a ready-to-use PVDF western blot membrane containing denatured protein lysates manufactured from Novus extensive Human Clinical Tissue Lysate collection. Each blot contains 14 lanes of alternating tumor (T) and matched normal adjacent (NA) tissue lysates from 7 patient donors. Incorporating both T and NA on the blot enables protein expression analysis of the tumor and microenvironment. The tumor microenvironment is increasingly being recognized as a major factor in influencing malignant progression and metastatic potential.Cancer is a heterogeneous disease and the presence of multiple donors on a single blot enables rapid screening of protein expression variability between T/NA from different individuals and at different disease stages. OncoPair INSTA-Blots&8286; are available for a wide range of tumor types and stages. The product line is manufactured from donor patient tissue obtained from established hospital-based collection sites around the world. Tissues are collected under strict bioethical standards using IRB and HIPAA approved protocols. These protocols ensure patient confidentiality, safety, and informed consent. Tissues are flash frozen at collection sites within minutes of removal, maintained in liquid nitrogen and processed into lysates using protocols optimized for extracting proteins from tissues. Lysates are denatured for OncoPair INSTA-Blot&8286; production; native lysates are available for follow up proteomic studies. OncoPair INSTA-Blots&8286; and lysates are also useful in conjunction with the Cell Line and Normal Tissue INSTA-Blots&8286; and lysates for comprehensive antibody validation and to profile antibody reactivity and protein expression patterns across species and between tissues and cells lines. The OncoPair INSTA-Blots&8286; are proteomic discovery tools and are useful for screening the expression of various proteins in tumor and normal adjacent tissues from various donors. Researchers may want to follow up on their results by further analysis with the corresponding individual lysates when available. Show More | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PreparationMethod | Tissue specimens were homogenized in modified RIPA buffer to obtain the soluble proteins and centrifuged to clarify. The concentration of protein in each lysate was determined by a standard protein assay and standardized to 1 mg/ml. Sample buffer was added to the soluble fraction and approximately 14 ug/lane of protein was run and then transferred to PVDF membrane.Soluble fraction extraction buffer (extract 1): PBS at pH 7.4, 1 ug/ml Aprotinin, 1 mM NaF -Modified RIPA buffer: 1 mM EDTA, 1 ug/ml Pepstatin-A, 0.1% SDS, 0.25% Na deoxycholate, 1 ug/ml Leupeptin, 1 mM PMSF, 1 mM Na3VO45X Sample buffer: 50 ml glycerol, 15 g SDS, 3.819 g Tris, pH 6.8, 25 ml 2-ME, 100 mg bromophenol blue, final volume of 100 ml with DI H2O. |
Application Notes | Use in Western blot reported in scientific literature (PMID 25985210) | |
Publications |
|
Accelerate Scientific Discovery by Developing Unique Products
The mission of Novus Biologicals, LLC is to accelerate scientific discovery by developing and marketing unique products for the lifesciences. Novus Biologicals is also organized to provide the biological research community with a mechanism for commercializing unique biological materials. We also focus on continually monitoring scientific trends and supply materials to serve these trends. By making these products widely available to institutional and commercial researchers, Novus Biologicals plays an important role in furthering biological research.
All of Novus Biologicals products are supplied with detailed technical information and ongoing support. By serving both niche and emerging markets, Novus Biologicals has built solid partnerships with our customers. Contact us for more information.
Novus Biologcials is part of the Bio-Techne family which includes: